Hosted on MSN1mon
Amneal gains FDA approval for dementia and oncology drugs
Looking ahead, Amneal has confirmed its revenue and adjusted EBITDA guidance for 2024, projecting ranges of $2.7 billion to $2.8 billion and $610 million to $630 million, respectively. The company ...
Benzinga.com14d
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars
Amneal reported Q4 sales of $730.52M, up 18% Y/Y, beating estimates, while adjusted EPS of $0.12 missed the $0.15 consensus. 2025 guidance: Revenue of $3B-$3.1B, adjusted EPS of $0.65-$0.70, and ...
Benzinga.com17d
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock
JP Morgan upgraded Amneal to Overweight, raising its price target to $12, citing strong generics growth and expanding biosimilar adoption. Every week, our Whisper Index uncovers five overlooked ...
Yahoo Finance10d
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
BRIDGEWATER, N.J., March 03, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and ...
Nasdaq14d
AMNEAL PHARMACEUTICALS Earnings Results: $AMRX Reports Quarterly Earnings
AMNEAL PHARMACEUTICALS ($AMRX) posted quarterly earnings results on Friday, February 28th. The company reported earnings of $0.12 per share, missing estimates of $0. ...